Measurable residual disease assessed by mass spectrometry in peripheral blood in multiple myeloma in a phase II trial of carfilzomib, lenalidomide, dexamethasone and autologous stem cell transplantation
Benjamin A. Derman, Andrew Stefka, Ken Jiang, Amanda McIver, Tadeusz Kubicki, Jagoda Jasielec, Andrzej Jakubowiak
Topics & Concepts
CarfilzomibLenalidomideMultiple myelomaMedicineDexamethasoneMinimal residual diseaseTransplantationAutologous stem-cell transplantationInternal medicineOncologyHematopoietic stem cell transplantationImmunologyBone marrowMultiple Myeloma Research and TreatmentsProtein Degradation and InhibitorsMyeloproliferative Neoplasms: Diagnosis and Treatment